Stockscreener 앱 받기
3.04
6.46%
-0.21
시간 외 거래:
3.07
0.03
+0.99%
Adc Therapeutics Sa 주식(ADCT)의 최신 뉴스
ADC Therapeutics’ LOTIS-10 Study: A Potential Game-Changer in Lymphoma Treatment - TipRanks
What makes ADC Therapeutics SA stock price move sharplySmall Risk Large Return Trades - Newser
Why ADC Therapeutics SA stock attracts strong analyst attentionFree Market Sentiment Analysis - Newser
How ADC Therapeutics SA stock performs during market volatilityFree Exclusive Stock Market Insights - Newser
ADC Therapeutics (NYSE:ADCT) Shares Down 4.2%What's Next? - MarketBeat
ADC Therapeutics (NYSE:ADCT) Shares Down 4.2% – Here’s Why - Defense World
ADC Therapeutics announces $100M private financing - MSN
ADC Therapeutics Makes Grant to New Employee Under Inducement Plan - The Malaysian Reserve
ADC Therapeutics (ADCT) Files Prospectus for Share Sale - GuruFocus
ADCT SEC FilingsAdc Therapeutics Sa 10-K, 10-Q, 8-K Forms - Stock Titan
The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough? - Weekly Voice
ADC reports data from lymphoma trial, streamlines operations - MSN
ADC Therapeutics (NYSE:ADCT) Stock Rating Upgraded by Royal Bank Of Canada - MarketBeat
ADC Therapeutics (ADCT) Price Target Lowered by RBC Capital | AD - GuruFocus
ADC Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes - Quantisnow
Adc Therapeutics SA (NYSE: ADCT) Continues Its Downward Trend - Stocksregister
ADC Therapeutics Announces Updated ZYNLONTA Investigator-Initiated Trial Data in R/R Marginal Zone Lymphoma Presented at 18th International Conference on Malignant Lymphoma - marketscreener.com
ZYNLONTA shows 85% response rate in marginal zone lymphoma trial By Investing.com - Investing.com Nigeria
ZYNLONTA shows 85% response rate in marginal zone lymphoma trial - Investing.com Australia
Breakthrough Lymphoma Treatment: ZYNLONTA Shows 85% Response Rate with 27-Month Durability in Latest Trial - Stock Titan
Switzerland: ADC Therapeutics raises US$100m from PIPE financing - Investors in Healthcare
Guggenheim Reaffirms Buy Rating for ADC Therapeutics (NYSE:ADCT) - Defense World
ADC Therapeutics (NYSE:ADCT) Stock Price Expected to Rise, Guggenheim Analyst Says - Defense World
Analysts Set Expectations for ADCT FY2026 Earnings - MarketBeat
Guggenheim Raises Price Target for ADC Therapeutics (ADCT) | ADCT Stock News - GuruFocus
ADC Therapeutics (ADCT) Price Target Raised Amid Strategic Moves - GuruFocus
ADC Therapeutics (ADCT) Secures $100M in PIPE Financing to Boost ZYNLONTA Development - GuruFocus
Layoff Tracker: ADC Therapeutics Cutting 30% of Staff, Closing London Research Facility - BioSpace
ADC Therapeutics (NYSE:ADCT) Price Target Raised to $10.00 at Guggenheim - MarketBeat
ADC Therapeutics price target raised to $10 from $7 on positive trial data By Investing.com - Investing.com South Africa
ADC Therapeutics price target raised to $10 from $7 on positive trial data - Investing.com India
ADC Therapeutics (ADCT) Price Target Raised Amid Strategic Moves | ADCT Stock News - GuruFocus
ADC Therapeutics Announces Updated Data from LOTIS-7 Clinical Trial Presented at the European Hematology Association 2025 Congress - The Malaysian Reserve
ADC Therapeutics Tightens Belt And Targets New Frontiers - Finimize
ADC Therapeutics raises $100 million in private placement By Investing.com - Investing.com South Africa
ZYNLONTA-glofitamab combo shows 93.3% response rate in lymphoma trial By Investing.com - Investing.com South Africa
Transcript : ADC Therapeutics SASpecial Call - MarketScreener
ADC Therapeutics Announces $100M Private Placement - TipRanks
ADC Therapeutics to Cut 30% of Workforce, Shutter UK Site - MarketScreener
ADC Therapeutics : Corporate and Clinical Update June 2025 - MarketScreener
ADC Therapeutics (ADCT) Secures $100 Million in Private Equity F - GuruFocus
Adc Therapeutics Announces Updated Data from Lotis-7 Clinical Trial Presented At the European Hematology Association 2025 Congress - MarketScreener
ADC Therapeutics (ADCT) Secures $100 Million in Private Equity Financing | ADCT Stock News - GuruFocus
ADC Therapeutics raises $100 million in private placement - Investing.com Australia
ADC Therapeutics Announces $100 Million Private Placement Extending Expected Cash Runway into 2028 - GuruFocus
Adc Therapeutics Announces $100 Mln Private Placement Extending Expected Cash Runway Into 2028 - marketscreener.com
ZYNLONTA-glofitamab combo shows 93.3% response rate in lymphoma trial - Investing.com
3.40%
2.49%
자본화:
|
볼륨(24시간):